Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27548749 | 0.98 | CYP1A2 (0.41) | CYP1A2KDM4EALDH1A1TDP1ALOX15 | |
| SCHEMBL5042450 | 0.90 | ALOX15 (0.35) | CYP1A2ALOX15 | |
| SCHEMBL27469787 | 0.90 | ALOX15 (0.35) | CYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL27471279 | 0.89 | ALOX15 (0.34) | CYP1A2ALOX15 | |
| SCHEMBL5042658 | 0.80 | ALOX15 (0.33) | KDM4EALOX15 | |
| SCHEMBL5042569 | 0.79 | USP2 (0.36) | CYP1A2ALDH1A1 | |
| SCHEMBL197847 | 0.77 | ALDH1A1 (0.39) | CYP1A2ALDH1A1 | |
| SCHEMBL28350691 | 0.75 | FUCA1 (0.32) | ALOX15 | |
| SCHEMBL5038657 | 0.75 | FUCA1 (0.32) | ALOX15 | |
| Hydrochloric Acid SCHEMBL3819339 | 0.75 | ALDH1A1 (0.38) | CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007120485-A2 | METHODS OF TREATING PAIN WITH ALKYLXANTHINES AND ANTIEPILEPTICS AND COMPOSITIONS FOR USE THEREFOR | CINERGEN, LLC (US) | 2007-10-25 | — | — | WO | claimed |
| JP-3884486-B2 | — | — | 2007-02-21 | — | — | JP | claimed |
| EP-1554237-A4 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT INC (US) | 2006-11-02 | — | — | EP | claimed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| CN-1675165-A | Method for synthesizing acyloxyalkyl derivatives of GABA analogs | XENOPORT INC (US) | 2005-09-28 | — | — | CN | claimed |
| EP-1554237-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | Xenoport, Inc. (US) | 2005-07-20 | — | — | EP | claimed |
| EP-1549302-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | claimed |
| CN-1626069-A | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy | WARNER LAMBERT CO (US) | 2005-06-15 | — | — | CN | claimed |
| WO-2004006901-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20040010035-A1 | Gastrointestinal compositions | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | claimed |
| US-20040010034-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| WO-2003104184-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| CN-1344245-A | Inhibitors of branched chain amino acid dependent aminotransferases and their use in the treatment of diabetic retinopathy | WARNER LAMBER CO (US) | 2002-04-10 | — | — | CN | claimed |
| US-20020032235-A1 | Anti-inflammatory method | SCHRIER DENIS (US) | 2002-03-14 | — | — | US | claimed |
| JP-2002506449-A | — | — | 2002-02-26 | — | — | JP | claimed |
| US-6329429-B1 | ADMINISTERING ANTI-INFLAMMATORY COMPOUND COMPRISING CYCLIC AMINO ACID OR ITS DERIVATIVE TO THERAPY | WARNER-LAMBERT COMPANY | 2001-12-11 | — | — | US | claimed |
| EP-0994704-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010034-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | CYP1A2 752/4885KDM4E 4537/4885ALDH1A1 1487/4885 |
| US-20040010035-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | CYP1A2 752/4885KDM4E 4537/4885ALDH1A1 1487/4885 |
| US-20020032235-A1 | Anti-inflammatory method | GABRB2, GABRB1, GABRB3 | CYP1A2 729/4885KDM4E 3731/4885ALDH1A1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.